Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Travere Therapeutics, Inc. (TVTX : NSDQ)
 
 • Company Description   
Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

Number of Employees: 310

 
 • Price / Volume Information   
Yesterday's Closing Price: $24.60 Daily Weekly Monthly
20 Day Moving Average: 912,684 shares
Shares Outstanding: 63.51 (millions)
Market Capitalization: $1,562.45 (millions)
Beta: 0.72
52 Week High: $31.65
52 Week Low: $12.75
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.89% -1.88%
12 Week -9.43% -0.42%
Year To Date -20.75% -3.17%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3611 VALLEY CENTRE DR SUITE 300
-
SAN DIEGO,CA 92130
USA
ph: 888-969-7879
fax: 302-645-1280
ir@travere.com https://travere.com
 
 • General Corporate Information   
Officers
Eric M. Dube - Chief Executive Officer
Laura Clague - Chief Financial Officer
Sandra Calvin - Vice President; Corporate Controller and Chief Acc
Stephen Aselage - Director
Roy D. Baynes - Director

Peer Information
Travere Therapeutics, Inc. (CORR.)
Travere Therapeutics, Inc. (RSPI)
Travere Therapeutics, Inc. (CGXP)
Travere Therapeutics, Inc. (BGEN)
Travere Therapeutics, Inc. (GTBP)
Travere Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 89422G107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 63.51
Most Recent Split Date: (:1)
Beta: 0.72
Market Capitalization: $1,562.45 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.89 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.71 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 7.51
Price/Cash Flow: -
Price / Sales: 6.84
EPS Growth
vs. Year Ago Period: -25.00%
vs. Previous Quarter: -42.86%
Sales Growth
vs. Year Ago Period: 2.28%
vs. Previous Quarter: -15.31%
ROE
03/31/22 - -70.33
12/31/21 - -55.22
09/30/21 - -82.45
ROA
03/31/22 - -25.86
12/31/21 - -23.52
09/30/21 - -34.58
Current Ratio
03/31/22 - 5.28
12/31/21 - 4.70
09/30/21 - 5.12
Quick Ratio
03/31/22 - 5.23
12/31/21 - 4.64
09/30/21 - 5.06
Operating Margin
03/31/22 - -88.46
12/31/21 - -79.16
09/30/21 - -113.07
Net Margin
03/31/22 - -88.46
12/31/21 - -79.16
09/30/21 - -113.07
Pre-Tax Margin
03/31/22 - -88.40
12/31/21 - -78.99
09/30/21 - -113.10
Book Value
03/31/22 - 3.28
12/31/21 - 4.93
09/30/21 - 5.02
Inventory Turnover
03/31/22 - 1.04
12/31/21 - 0.95
09/30/21 - 0.97
Debt-to-Equity
03/31/22 - 1.80
12/31/21 - 0.75
09/30/21 - 0.73
Debt-to-Capital
03/31/22 - 64.27
12/31/21 - 42.86
09/30/21 - 42.12
 

Powered by Zacks Investment Research ©